With actionability of Alzheimer’s Disease on the horizon, our results encourage engaging a discussion on whether reporting these variants to patient-carriers is desirable, possibly in combination with APOE genotype. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.